Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

5.84EUR
22 Feb 2019
Change (% chg)

€0.06 (+1.04%)
Prev Close
€5.78
Open
€5.80
Day's High
€5.90
Day's Low
€5.75
Volume
44,813
Avg. Vol
131,640
52-wk High
€10.34
52-wk Low
€4.36

Latest Key Developments (Source: Significant Developments)

Nicox Enters Into Bond Financing For Up To 20 Million Euros From Kreos Capital
Friday, 25 Jan 2019 

Jan 25 (Reuters) - NICOX SA ::REG-NICOX EXTENDS CASH RUNWAY BEYOND 2020 WITH BOND FINANCING FROM KREOS CAPITAL OF UP TO €20 MILLION.EUR 8 MILLION DRAWN DOWN IMMEDIATELY; TWO ADDITIONAL TRANCHES OF EUR 7 MILLION AND EUR 5 MILLION AVAILABLE IN FUTURE TO BE DRAWN DOWN AT NICOX'S DISCRETION.INCLUDING CURRENT CASH ON HAND AND EXPECTED REVENUES, USE OF FULL BOND FINANCING COULD EXTEND NICOX'S CASH RUNWAY BEYOND 2020.AS PART OF THIS FINANCING, KREOS WILL RECEIVE 308,848 WARRANTS FOR 308,848 NICOX SHARES.FINANCING OF UP TO EUR 20 MILLION, STRUCTURED AS BONDS, CONSIST OF 3 TRANCHES.FIRST TRANCHE OF EUR 8 MILLION WILL BE DRAWN DOWN ON OR ABOUT FEBRUARY 1(ST ), 2019.COMPANY HAS OPTION, BUT NO OBLIGATION, TO DRAW DOWN A FURTHER MAXIMUM AMOUNT OF EUR 7 MILLION ON AUGUST 1(ST), 2019.  Full Article

Nicox End-Dec. Cash And Cash Equivalents Of EUR 22.0 Million
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - NICOX SA ::REG-NICOX FOURTH QUARTER 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.NET REVENUE FOR YEAR 2018 OF EUR 4.0 MILLION.AS OF DECEMBER 31, 2018, NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF EUR 22.0 MILLION.NICOX WILL NO LONGER RECEIVE $1 MILLION MILESTONE PAYMENT ASSOCIATED WITH DELIVERY OF COMMERCIAL PRODUCT TO EYEVANCE BUT REMAINS ELIGIBLE FOR UP TO $3 MILLION OF A POTENTIAL FUTURE MILESTONE PAYMENT.  Full Article

Vyzulta Approved In Canada By Nicox's Partner
Friday, 4 Jan 2019 

Jan 4 (Reuters) - NICOX SA ::VYZULTA APPROVED IN CANADA BY NICOX'S PARTNER.VYZULTA (TM)IS INDICATED FOR REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.NICOX RECEIVES INCREASING TIERED NET ROYALTIES OF 6% TO 12% ON GLOBAL SALES OF VYZULTA (TM).NICOX RECEIVES UP TO $150 MILLION IN NET SALES MILESTONES LINKED TO GLOBAL SALES.  Full Article

Nicox Enters Into Collaboration With Novaliq
Friday, 21 Dec 2018 

Dec 21 (Reuters) - NICOX SA ::FOCUSES RESEARCH ACTIVITIES ON NOVEL NO-DONATING PDE5 INHIBITORS FOR GLAUCOMA AND ENTERS INTO COLLABORATION WITH NOVALIQ.COLLABORATION WITH NOVALIQ TO ACCESS NOVEL FORMULATION TECHNOLOGY FOR THESE NEW COMPOUNDS.ENCOURAGING PRECLINICAL EFFICACY DATA ON NO-DONATING PDE5 INHIBITORS.FOCUSING OF RESEARCH ACTIVITIES ON MOST PROMISING NEW PHARMACOLOGIC CLASSES.EXPECTS TO BE ABLE TO ANNOUNCE A PRECLINICAL CANDIDATE FROM ONE OF THESE PROGRAMS IN THE NEXT 18 MONTHS.  Full Article

Nicox Reports Cash And Cash Equivalents Of 25.7 Million Euros at Sept 30
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - NICOX SA ::REG-NICOX THIRD QUARTER 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.NCX 470 PHASE 2 CLINICAL STUDY INITIATED IN Q3 2018.NET REVENUE IN Q3 FROM VYZULTA SALES INCREASED BY 66% COMPARED TO Q2 2018.AS OF SEPTEMBER 30, 2018, CO HAD CASH AND CASH EQUIVALENTS OF €25.7 MILLION AS COMPARED WITH €32.7 MILLION AT JUNE 30.NET REVENUE FOR THE THIRD QUARTER OF 2018 WAS $0.438 MILLION.  Full Article

Nicox And Fera Pharmaceuticals Amend Their Agreement For Naproxcinod
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - NICOX SA ::REG-NICOX AND FERA PHARMACEUTICALS TO FOCUS ON A RARE DISEASE INDICATION FOR NAPROXCINOD.POTENTIAL SALES-BASED MILESTONE INCREASED TO $40 MILLION IF ANNUAL SALES REACH $1 BILLION.  Full Article

Nicox End-June Net Loss Is At 7.6 Million Euros
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - NICOX SA ::NCX 470 PHASE 2 CLINICAL STUDY INITIATED IN Q3 2018.AND CONTINUE DELIVERING ON ALL OBJECTIVES IN LINE WITH OUR GROWTH STRATEGY.NICOX EXPECTS TO REPORT TOP-LINE DATA FROM THIS PHASE 2 STUDY IN SECOND HALF OF 2019..PRECLINICAL AND FORMULATION DEVELOPMENT OF NCX 4251 IS CONTINUING ON TRACK FOR Q1 2019 IND SUBMISSION TO U.S FDA TO ENABLE A PHASE 2 STUDY.WE EXPECT TO SHIP COMMERCIAL PRODUCT AND TRADE SAMPLES FOR ZERVIATE 0.24% TO OUR PARTNER EYEVANCE BY Q1 2019.EYEVANCE TO LAUNCH ZERVIATETM IN UNITED STATES IN TIME FOR 2019 SPRING ALLERGY SEASON.NET REVENUE(1) FOR FIRST HALF OF 2018 WAS EUR 0.3 MILLION.OPERATING EXPENSES FOR FIRST HALF OF 2018 WERE EUR 10.0 MILLION FOR FIRST SIX MONTHS OF 2018 COMPARED TO EUR 10.2 MILLION FOR FIRST SIX MONTHS OF 2017.A NET LOSS OF EUR 7.6 MILLION FOR SIX MONTHS ENDED JUNE 30, 2018.AS OF JUNE 30, 2018 CASH AND CASH EQUIVALENTS OF EUR 32.7 MILLION AS COMPARED WITH EUR 36.3 MILLION AT MARCH 31, 2018 AND EUR 41.4 MILLION AT DECEMBER 31, 2017.  Full Article

Nicox Initiates Phase 2 Study Of NCX 470 In Open-Angle Glaucoma And Ocular
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - NICOX SA ::NICOX INITIATES PHASE 2 STUDY OF NCX 470 IN OPEN-ANGLE GLAUCOMA AND OCULAR.STUDY TO RANDOMIZE 420 PATIENTS IN CLINICAL SITES ACROSS U.S..TOP-LINE RESULTS EXPECTED H2 2019.TARGETS $5 BILLION WORLDWIDE GLAUCOMA MARKET.INITIATION OF A PHASE 2 CLINICAL STUDY EVALUATING NCX 470.  Full Article

Nicox Plans Start Of Phase 2 Clinical Study For NCX 470 In Q3 2018
Tuesday, 17 Jul 2018 

July 17 (Reuters) - NICOX SA ::NICOX Q2 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.Q3 2018: PLANNED START OF PHASE 2 CLINICAL STUDY FOR NCX 470 FOR THE REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.FALL 2018: EXPECTED COMMERCIAL LAUNCH OF ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% IN THE UNITED STATES BY PARTNER EYEVANCE PHARMACEUTICALS, LLC..Q1 2019: PLANNED U.S. INVESTIGATIONAL NEW DRUG SUBMISSION TO THE U.S. FDA FOR NCX 4251.AS OF JUNE 30, 2018, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €32.6 MILLION VERSUS €36.3 MILLION AT MARCH 31, 2018.VYZULTA SALES GREW SUBSTANTIALLY IN THE Q2.  Full Article

Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer
Friday, 20 Apr 2018 

April 20 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER.SELLAS LIFE SCIENCES GROUP INC - INTERIM CHIEF FINANCIAL OFFICER ALEKSEY KRYLOV WILL REMAIN WITH SELLAS UNTIL JULY 15.SELLAS LIFE SCIENCES GROUP INC - MACK MOST RECENTLY SERVED AS A CONSULTING CFO, MOST RECENTLY WITH NICOX, SA.  Full Article

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.